Unknown

Dataset Information

0

Percutaneous Hepatic Perfusion (PHP) with Melphalan in Liver-Dominant Metastatic Uveal Melanoma: The German Experience.


ABSTRACT: Percutaneous hepatic perfusion (PHP) delivers high-dose melphalan to the liver while minimizing systemic toxicity via filtration of the venous hepatic blood. This two-center study aimed to examine the safety, response to therapy, and survival of patients with hepatic-dominant metastatic uveal melanoma (UM) treated with PHP. A total of 66 patients with liver-dominant metastasized uveal melanoma, treated with 145 PHP between April 2014 and May 2020, were retrospectively analyzed with regard to adverse events (AEs; CTCAE v5.0), response (overall response rate (ORR)), and disease control rate (DCR) according to RECIST1.1, as well as progression-free and overall survival (PFS and OS). With an ORR of 59% and a DCR of 93.4%, the response was encouraging. After initial PHP, median hepatic PFS was 12.4 (confidence interval (CI) 4-18.4) months and median OS was 18.4 (CI 7-24.6) months. Hematologic toxicity was the most frequent AE (grade 3 or 4 thrombocytopenia after 24.8% of the procedures); less frequent was grade 3 or 4 hepatic toxicity (increased aspartate transaminase (AST) and alanine transaminase (ALT) after 7.6% and 6.9% of the interventions, respectively). Cardiovascular events included four cases of ischemic stroke (2.8%) and one patient with central pulmonary embolism (0.7%). In conclusion, PHP is a safe and effective salvage treatment for liver-dominant metastatic uveal melanoma. Serious AEs-though rare-demand careful patient selection.

SUBMITTER: Dewald CLA 

PROVIDER: S-EPMC8749811 | biostudies-literature |

REPOSITORIES: biostudies-literature

Similar Datasets

| S-EPMC8469397 | biostudies-literature
| S-EPMC8284610 | biostudies-literature
| S-EPMC7801354 | biostudies-literature
| S-EPMC4354564 | biostudies-literature
| S-EPMC8555734 | biostudies-literature
| S-EPMC7484678 | biostudies-literature
| S-EPMC8758076 | biostudies-literature
| S-EPMC4024156 | biostudies-literature
| S-EPMC5558752 | biostudies-literature
| S-EPMC8480350 | biostudies-literature